Molbio Diagnostics Reports Q2 and H1 FY27 Financial Results and Growth Outlook
Molbio Diagnostics Ltd · Investor Presentation · 05 Nov 2026, 11:07 pm
Molbio Diagnostics Reports Q2 and H1 FY27 Financial Results and Growth Outlook Molbio Diagnostics reported Q2 FY27 revenue from operations of ₹259.0 Cr, EBITDA of ₹49.7 Cr (18.8% margin), and PAT of ₹7.7 Cr, impacted by 1–1.5 months of rate-contract negotiations. For H1 FY27, revenue reached ₹667.4 Cr with EBITDA at ₹153.4 Cr (22.7% margin) and PAT of ₹60.4 Cr. Operating cash flow turned positive to ₹167.1 Cr. Management reiterated its 25% topline growth guidance for FY27, supported by non-linear revenue seasonality (H1 historically generating 35–45%), ongoing global expansion, and pipeline extensions into veterinary and digital pathology.
Original exchange filing (PDF)
More announcements from Molbio Diagnostics Ltd
- Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026 · 11 Nov 2026
- Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company · 07 Nov 2026
- Audio Recording of Earnings call held on November 05,2026 for the quarter and half year ended September 30,2026. · 06 Nov 2026
- Outcome of Board meeting held on Thursday, November 05, 2026 · 06 Nov 2026
- Outcome of the Board Meeting · 05 Nov 2026
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026. · 05 Nov 2026
- To consider and approve the Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 05 Nov 2026
